Sales & Marketing

How to build a modular content system to optimize content creation and delivery, Using Al-powered engines that know your HCP's viewing behavior, using discomfort as an advantage and much more.

How media consumption is evolving and modifying digital and social strategies to best capture the behavioral changes of HCPs towards digital platforms.

EVERSANA honored for innovative use of artificial intelligence in video production — enhancing educational content development for the life science industry.

The combined company is expected to deliver a superior health care experience and drive better outcomes.

Rohit Gupta, vice president of analytics strategy and transformation at Beghou Consulting, addresses the controversial middlemen of the drug pricing world, the pharmacy benefit managers (PBMs). Can increased competition and other innovative solutions loosen their grip and prevent further consolidation?

Indegene's Jitesh Sah, Vice President, Analytics and Vikas Mahajan, Sr. Director, Data & Analytics chat with senior editor Fran Pollaro about the challenge of data drift.

TikTok is facing a potential ban in the US over national security concerns and advertisers are avoiding the platform or putting together contingency plans.

The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.

Pharma firm is seeking buyers for front-of-eye portfolio and assets include Xiidra, which had $487 million of sales in 2022.

Fran Pollaro talks with Cathi Ahearn, senior vice president, worldwide commercial portfolio strategy, Bristol Myers Squibb about impediments and solutions to break down silos in order to get medications in the hands of patients faster.

Havas Health & You to navigate complexities around value, access, pricing, and reimbursement.

Pfizer will pay pay $229 a share in cash for the cancer specialist.

Acquisition will bolster Sanofi's work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks.

Sumitovant Biopharma has completed its acquisition of Myovant Sciences in an all-cash deal worth $1.7 billion, with Myovant being delisted from the New York Stock Exchange and its shares no longer publicly traded.

While industry financial markets continued to experience subdued dollar volumes in 2022, dealmaking held steady—with factors such as pharma pursuing strategic priorities and biotech funding woes playing major roles.

How platforms like ChatGPT could transform engagement models.

Building on Organon’s prior FP2030 commitment, the company announces $30 million in new funding to fuel global action and community-driven solutions needed by the 121 million women and girls who experience unplanned pregnancies each year.

Nelarabine Injection ensures access to a lifesaving treatment, particularly for children, that historically has been in shortage.

Standard Media Index's latest data suggests that 2022 may have been a tipping point in the transition to digital pharma advertising.

Pharmaceutical companies are increasingly using radio advertising, both traditional and digital.

Survey: HCPs Rank Corporate Reputation as Leading Factor After Drug Efficacy and Safety

Enterprise generative AI focused on life sciences to bring life-saving drugs to market faster.

The drug is Xspray Pharma's first innovative cancer therapy and is set to launch later in 2023.

Blueprint Medicines Corporation will regain global commercialization and development rights to Gavreto (pralsetinib).

The therapy to treat a type of inherited bleeding disorder known as hemophilia A is expected to launch in the United States in April.